At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Dividend-paying stocks can really boost an individual investor's portfolio. If you're in the market for some no-brainer ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas ...

A pharmacist administers the Pfizer-BioNTech Covid-19 vaccine to an attendee of an immunization event at the L.A. Care and ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Rath began a Law Society of Alberta disciplinary hearing Tuesday on three misconduct charges, including allegations he ...

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced ...

The risk for CV events was increased among patients who were hospitalized for COVID-19, though it was heightened by preexisting CV conditions and mitigated by vaccination.

Pfizer is gearing up for a major push into the obesity drug market, drawing parallels to its success with Viagra. Despite ...